Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Open-Label, Safety and Efficacy, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV211 in Subjects With T2-T3 Oral Squamous Cell Carcinoma Amenable to Surgery

X
Trial Profile

Phase 1/2, Open-Label, Safety and Efficacy, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV211 in Subjects With T2-T3 Oral Squamous Cell Carcinoma Amenable to Surgery

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary)
  • Indications Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus First in man; Therapeutic Use
  • Sponsors Privo Technologies
  • Most Recent Events

    • 16 Jan 2024 Status changed from not yet recruiting to recruiting.
    • 30 May 2023 Status changed from planning to not yet recruiting.
    • 25 Feb 2022 According to a Privo Technologies media release, the company has received $2.5M grant as part of National Cancer Institute's Notice of Special Interest announcement. The award supports the first-in-man clinical study of PRV211. The clinical trial will initially enroll patients with advanced head and neck cancer and will then recruit patients with other solid tumors. The company plans to open enrollment for this study in 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top